Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer

Pioneering with PARP inhibition: rationale for maintenance therapy in newly diagnosed ovarian cancer

Date

22 Sep 2020

Session

AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer

Presenters

Thomas Herzog

Authors

T. Herzog

Author affiliations

  • Gynecologic Oncology, University of Cincinnati Cancer Institute, University of Cincinnati Medical Center, 45219 - Cincinnati/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.